Clinical Trial Update: Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab and acalabrutinib in newly diagnosed post-transplant lymphoproliferative disorder was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Deepa Jagadeesh | Conditions: Post-transplant Lymphoproliferative Disorder | Phase 2 | Status: TERMINATED | Results posted: 2024-04-10